Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
02:49am, Wednesday, 26'th Feb 2025
PALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate princi
- Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term debt facility lowers interest expense, eliminates near-term amortization
BridgeBio: Strong Start For Attruby
01:34pm, Thursday, 20'th Feb 2025
Attruby is off to a strong start in the United States, with more than 1,000 unique prescriptions in less than three months since FDA approval. I now see more patients on Attruby by year-end than I ant
BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates
09:55am, Thursday, 20'th Feb 2025
BridgeBio Pharma (BBIO) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $0.96 per share a year ago.
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
07:30am, Thursday, 20'th Feb 2025
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete T
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
04:01pm, Thursday, 13'th Feb 2025
PALO ALTO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
09:21am, Tuesday, 11'th Feb 2025
PALO ALTO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
09:30am, Wednesday, 15'th Jan 2025
Attruby's recent approval positions BBIO as a direct competitor to PFE's Vyndaqel in ATTR-CM. Attruby has a 42% reduction of heart failure risk with 90% TTR stabilization. So I think it could have a s
BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization
03:40pm, Tuesday, 14'th Jan 2025
BridgeBio CEO Neil Kumar joins CNBC's 'Power Lunch' to discuss the company's latest drug developments, how the drugs compares to competitors in the space, and more.
Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength?
06:01am, Tuesday, 14'th Jan 2025
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
02:22pm, Monday, 13'th Jan 2025
Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
11:00am, Monday, 13'th Jan 2025
- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
07:30am, Wednesday, 08'th Jan 2025
PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
07:18am, Friday, 13'th Dec 2024
PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
SANTA CRUZ, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced to
